Condition
Rosacea, Erythematotelangiectatic
Total Trials
5
Recruiting
1
Active
1
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (4)
P 1 (1)
Trial Status
Completed3
Recruiting1
Not Yet Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07521462Not ApplicableNot Yet RecruitingPrimary
Dermocosmetic Treatment for Facial Redness in Rosacea With or Without Laser Therapy
NCT06801717Not ApplicableRecruiting
Rosacea Radiofrequency Microneedling
NCT06434519Not ApplicableCompletedPrimary
Metronidazole SC Penetrance With Moisturizers
NCT06908915Not ApplicableCompletedPrimary
Long Pulse 1064 nm Nd:YAG Laser in the Treatment of Erythematotelangiectatic Rosacea and Other Erythematous Telangiectatic Facial Conditions
NCT05616923Phase 1CompletedPrimary
Topical Mitogenic-Activated Protein Kinase (MAPK) Inhibition in Rosacea
Showing all 5 trials